Revenue climbed 45.8 percent to 1.5 trillion won, also a quarterly high, and the operating margin widened 4.7 percentage points to 34 percent.
Quarterly operating profit topped 500 billion won for the first time since the company’s founding.
Operating profit for the first nine months jumped 85.2 percent to 1.28 trillion won.
Omlyclo, Celltrion’s near-identical version of the asthma and allergy drug Xolair, led gains in Europe. The drug is sold in 26 countries there and held more than 90 percent of Spain’s market as of July, according to local market data cited by the company.
Steqeyma and Yuflyma, its versions of Stelara and Humira, took 15 percent and 11 percent of the U.S. market in August.
Omlyclo launched in the United States this month as the first Xolair biosimilar there and won preferred status with Optum, a major pharmacy benefit manager.
“We will do our utmost to achieve our fourth-quarter and annual business plans, building on growth drivers such as the U.S. launch of Omlyclo and expanded supply in Europe,” a Celltrion official said.
AJP Takeaways
- Celltrion reported preliminary third-quarter 2026 operating profit of 510 billion won on Oct. 12, 2026, up 69.2 percent from a year earlier and a quarterly record.
- Third-quarter revenue rose 45.8 percent to 1.5 trillion won, and the operating margin widened to 34 percent, up 4.7 percentage points.
- Celltrion beat its own quarterly profit targets for a third straight quarter and launched its omalizumab biosimilar Omlyclo in the United States in October 2026.
Copyright ⓒ Aju Press All rights reserved.
